As of 2026-09-02 06:49 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. [1]
Alteogen Inc. signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous formulations using its ALT-B4 technology. [2][7] A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. [3] Novartis is conducting a thorough review of the observed safety events. [4]
The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. [5] Alteogen will receive royalties on net sales after commercialization in addition to the upfront potential value. [6] A March 19, 2027 CHF110/CHF140 put spread of 4,000 contracts indicates institutional hedging, buying protection against a drop to CHF110 while selling CHF140 puts to offset cost. [8]
Novartis AG may experience increased price swings as these large options positions play out, especially as September and October expiries approach, potentially triggering a gamma squeeze if the stock moves sharply toward key strikes. [9] The largest single options trade was over 4,300 contracts of the September 18, 2026 CHF130 call, amounting to 4,334 contracts traded with open interest of 9,743. [10] Total options volume for Novartis AG rose to 26,086 contracts by 10:10 a.m., with puts at 13,209 and calls at 12,877. [11]
The deal marks Alteogen's fourth ALT-B4 licensing agreement with a global pharmaceutical company this year. [12]Novartis suspendió ocho ensayos clínicos de una terapia experimental dirigida a trastornos autoinmunes y neurológicos a finales de agosto, tras la muerte de tres pacientes. [1]
Alteogen Inc. firmó un acuerdo de opción y licencia con Novartis AG por un valor de hasta 4,4 billones de wones (US$3.200 millones) para desarrollar y comercializar formulaciones subcutáneas utilizando su tecnología ALT-B4. [2][7] Un portavoz de Novartis declaró que los ensayos se suspendieron temporalmente tras el registro de respuestas inmunitarias graves en los tres casos. [3] Novartis está llevando a cabo una revisión exhaustiva de los eventos de seguridad observados. [4]
La compañía identificó la respuesta inmunitaria mortal como un riesgo de seguridad conocido en las terapias CAR-T, que modifican las células inmunitarias del paciente para reconocer y destruir células cancerosas. [5] Alteogen recibirá regalías sobre las ventas netas después de la comercialización, además del valor potencial inicial. [6] Un diferencial de venta CHF110/CHF140 del 19 de marzo de 2027 de 4.000 contratos indica cobertura institucional, comprando protección contra una caída a CHF110 mientras vende opciones de venta CHF140 para compensar el costo. [8]
Novartis AG podría experimentar mayores oscilaciones de precios a medida que se desarrollan estas grandes posiciones de opciones, especialmente con la aproximación de los vencimientos de septiembre y octubre, lo que podría desencadenar una compresión gamma si la acción se mueve bruscamente hacia los strikes clave. [9] La mayor operación de opciones individual fue de más de 4.300 contratos de la opción de compra CHF130 del 18 de septiembre de 2026, ascendiendo a 4.334 contratos negociados con un interés abierto de 9.743. [10] El volumen total de opciones de Novartis AG aumentó a 26.086 contratos a las 10:10 a.m., con opciones de venta en 13.209 y opciones de compra en 12.877. [11]
El acuerdo marca el cuarto acuerdo de licencia ALT-B4 de Alteogen con una compañía farmacéutica global este año. [12]
Proof12 sources · 3 publishers
What this stands on
Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. · elpaisvallenato.com
Alteogen Inc. signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous formulations using its ALT-B4 technology. · Yonhap News Agency
A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. · elpaisvallenato.com
Novartis is conducting a thorough review of the observed safety events. · elpaisvallenato.com
The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. · elpaisvallenato.com
Alteogen will receive royalties on net sales after commercialization in addition to the upfront potential value. · Yonhap News Agency
Novartis AG will have exclusive rights, through multiple options, to develop and commercialize SC formulations for multiple products using ALT-B4. · Yonhap News Agency
A March 19, 2027 CHF110/CHF140 put spread of 4,000 contracts indicates institutional hedging, buying protection against a drop to CHF110 while selling CHF140 puts to offset cost. · Investing.com
Novartis AG may experience increased price swings as these large options positions play out, especially as September and October expiries approach, potentially triggering a gamma squeeze if the stock moves sharply toward key strikes. · Investing.com
The largest single options trade was over 4,300 contracts of the September 18, 2026 CHF130 call, amounting to 4,334 contracts traded with open interest of 9,743. · Investing.com
Total options volume for Novartis AG rose to 26,086 contracts by 10:10 a.m., with puts at 13,209 and calls at 12,877. · Investing.com
The deal marks Alteogen's fourth ALT-B4 licensing agreement with a global pharmaceutical company this year. · Yonhap News Agency
1 of the 3 publishers publishes from South Korea. We do not know which country the other 2 publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Wednesday, September 2, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world3 publishers reported the events across 3 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
1 of the 3 publishers publishes from South Korea. We do not know which country the other 2 publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.